Zoom Logo

The 6th Annual ECSACOP Scientific Conference - Shared screen with speaker view - Recording 1/3
Johnstone Kumwenda
01:06:32
Do we have a constellation of symptoms that is more sensitive than the Jones criteria for picking up rheumatic fever. The problem we face is the huge number of other causes of fever in our communities. Health workers in these communities are unlikely to think of rheumatic fever as the primary cause of the child's illness.
Johnstone Kumwenda
01:08:16
do we need to advocate for other interventions for prevention? By the time we make a diagnosis, it is too late as your have said for many children.
Christopher P Pasi
01:12:16
Thank you Dr Okello. In the GOAL study how did you chose participants who would be assigned to the control group (i.e no antibiotic prophylaxis) when the had some form of valve lesion that I feel qualify them to get prophylaxis according to guidelines.
Henry Mwandumba
01:13:29
Very interesting and informative studies, thank you. One group at risk of progressive RHD and heart failure are young pregnant women. Do you think incorporating echocardiographic examination as part of antenatal assessment should be considered to identify patients and facilitate early intervention?
EAST CENTRAL & SOUTHERN AFRICA COLLEGE OF PHYSICIANS
01:14:05
Thank you for joining the 6th Annual ECSACOP Scientific Conference. Please register attendance at this link. https://forms.office.com/Pages/ResponsePage.aspx?id=pXV8DQKAXkm7nx8xCNyqKGK1gaZKJ-9KrrpB5_LbzUVUQkpaTENHSUdYWlNWWVFQRjVEVUxVTUlOMi4u
ESTHER GETAMBU
01:18:28
i seem to get the impression that strep infections with its associated rheumatic fever and heart disease ,actute glomerulonephritis are comparitively rare in Kenya cost compared to the highlands and cold places. suprisingly so is pneumococcus and grm negative meningococcus the only reason I can see that is common in these cocci is aspect of ventilation. in Mombasa people term to stay with windows open.
Leo Katsidzira
01:26:39
What are you doing with regards to genetic counselling ? This question frequently comes up in literature. Considerations for empowering our HIV counsellors (there are many in the ECSACOP region) to broaden their scope?
Henry Mwandumba
01:34:33
Excellent talks and discussion, thank you to both presenters.
Christopher Babua
01:37:29
Awesome presentations and discussions, big thank you to presenters and moderators of the first session.
Johnstone Kumwenda
01:44:59
Was the placebo group on optimized background treatment of DM?
Paul Kelly
02:10:18
Timekeepingā€¦.
Nancy Wamithi
02:22:02
Dear Panelists, please answer questions on the chat.
Johnstone Kumwenda
02:24:03
Many of our rural folks may not have capacity to see how their stool looks like. Steatorrhea may not therefore be an important consideration in the history. Can this be replaced by other important considerations in the history?
Peter Waitt
02:31:36
Very good talk on functional GI conditions, how much are we teaching on these at medical schools?especially as we move beyond ibs in our understanding of functional disorders? Thanks
Mhoira Leng
02:33:59
Many thanks for an excellent session highlighting areas we need to understand more fully. Thanks for the challenge to do more research in the area of functional GI disorders Dr Kayumba
Henry Mwandumba
02:36:38
Thank you Drs Kayamba, Sood and Phiri for excellent and informative presentations, very helpful.
Violet Kayamba
02:48:10
@Kumwenda, yes those who use pit latrines cannot know about steatorrhea. So we just have to rely on other symptoms and investigation findings.
Violet Kayamba
02:50:52
@Peter Wait, I think the emphasis on FGID is not as much as it should be during training. These are the most common reason for GI consultations, and I think they are mis-diagnosed by many.
Peter Waitt
02:52:44
Thanks Violet, thinking of ways of countering the 'epidemic' of h pylori and typhoid based on single point serology alone.
Violet Kayamba
02:53:17
@Leng, this is important indeed. We do need to do more research particularly within our region.
Violet Kayamba
02:55:01
@Henry Mwandumba, Thank you!
Richard Sanya
02:55:26
Thank you Prof. Kamya for the presentation. Can you comment on mRNA based vaccines for malaria?
Pauline BYAKIKA-K
02:56:51
Thank you Prof Kamya.
Henry Mwandumba
02:57:27
Thank you Prof Kamya for the great talk. RTS,S requires multiple doses, Do you envisage there will be a challenge to fit the vaccine in already crowded childhood EPI programmes?
Nancy Wamithi
02:58:38
Thank you Dr Sood, Dr Phiri and Dr Kayamba for your excellent presentations.šŸ‘
Bright Nsokolo
02:59:03
Indeed Dr Kayamba. Less emphasis on FGID may be as a result of having relatively fewer patients presenting with FGID in public hospitals. FGIDs seem to be more common in people with a higher social economic status, hence more common in the private sector. Even if the prevalence may be the same, the poor ones are unlikely to seek medical attention for functional disorders probably because they have bigger problems to think about.
Alick Nkhoma
02:59:47
Regarding long term efficacy, how conserved is the antigen targeted by RTSS vaccine
Peace Bagasha
03:01:16
thank you so much for the excellent presentation Prof kamya, are there any reports on application of these vaccines for foreigners travelling to endemic areas
Violet Kayamba
03:02:39
@Nsokolo, we need to systematically interrogate this question. Are FGID really more common among the rich or is it a situation of the poor only coming for care when conditions are desperate?
EAST CENTRAL & SOUTHERN AFRICA COLLEGE OF PHYSICIANS
03:03:35
Thank you for joining the 6th Annual ECSACOP Scientific Conference. Please register attendance at this link. https://forms.office.com/Pages/ResponsePage.aspx?id=pXV8DQKAXkm7nx8xCNyqKGK1gaZKJ-9KrrpB5_LbzUVUQkpaTENHSUdYWlNWWVFQRjVEVUxVTUlOMi4u
James Kayima
03:24:33
At the roll out of DTG, there were concerns about its safety profile- much more than resistance. We had a lot of patients with diabetic emergencies and hepatotoxicity. What's the experience Malawi? Are we able to predict which patients will get the toxicity?
Henry Mwandumba
03:24:59
Thank you for a great talk Dr Muturi. The rare finding of Kaposiā€™s sarcoma is interesting, and I wonder whether rapid viral suppression by DTG-based ART is a contributing factor. Are you aware of any studies that have compared cancer incidence by ART regimen?
Vincent Kioi
03:35:35
With the plan to use integrase inhibitors for pre- and post-exposure prophylaxis against HIV, is there any evidence to suggest there will be increased rates of high level resistance to dolutegravir?
Eva Agnes Laker Odongpiny
03:42:55
first line studies had showed hardly any resistance to DTG on failure, what could be driving the findings in malawi
David Meya
03:45:57
Not sure if I missed it, how many of these ?8 patients were on DTG while on TB meds?
Henry Mwandumba
03:48:59
Thank you Tom, excellent talk and the rich discussion with important programme implications.
Tom Heller
03:50:35
@Eva Agnes Lasker Odongpiny. - looking at the total population with a suppression rate of >95% the resistance is also very small in Malawi. It is just that we want to keep an eye also to inform how to deal with those with high VL.
Tom Heller
03:53:33
@David Meya - only one of the 8 patients received TB treatment during the DTG and in this patient the DTG dose was doubled
Eva Agnes Laker Odongpiny
03:59:43
Very important signal to watch.Thank you Tom
Kondwelani John Mateyo
04:05:50
Brilliant work and modus operandi Deanna and team!
Henry Mwandumba
04:08:54
The virtual neurology curriculum would benefit many trainees across the continent, this is a brilliant approach, Deanna. Would trainees from outside Zambia have to pay to join?
Mhoira Leng
04:10:06
Thankyou for such a clear presentation with impressive outcomes for neurology training. The video assessment are very interesting. I also agree we must encourage oursleves as ECSACOP to extend specialist training accreditation
ELIZABETH NABIRYE
04:14:11
very informative presentations. have you already presented, I joined late
Henry Mwandumba
04:15:27
We are on the neurology and Respiratory Medicine sub-theme. Dr Mateyo is presenting now.
rumbidzayi chakwesha
04:17:18
Please may I have the registration link again.
EAST CENTRAL & SOUTHERN AFRICA COLLEGE OF PHYSICIANS
04:19:55
https://us02web.zoom.us/meeting/register/tZAofumrrTwpH9SEsYKajeX1N0IAzb6nY5g4?_x_zm_rtaid=MCdWZmnJS46shL2IKVx-8Q.1639819019632.d83eb0adcd32c28712c4921380835835&_x_zm_rhtaid=766
EAST CENTRAL & SOUTHERN AFRICA COLLEGE OF PHYSICIANS
04:20:28
Thank you for joining the 6th Annual ECSACOP Scientific Conference. Please register attendance at this link. https://forms.office.com/Pages/ResponsePage.aspx?id=pXV8DQKAXkm7nx8xCNyqKGK1gaZKJ-9KrrpB5_LbzUVUQkpaTENHSUdYWlNWWVFQRjVEVUxVTUlOMi4u
Lydia Nakiyingi
04:25:57
Questions in the chat are wellcome
Henry Mwandumba
04:30:11
Thank you Dr Mateyo for an exciting presentation. Do you know if post-TB chronic lung disease was specifically associated with severe Covid-19 and poor outcomes?
Alick Nkhoma
04:33:53
Excellent presentation and challenge Dr Mateyo
Nancy Wamithi
04:36:37
Can we please answer the questions in the chat
Faraj Tamimy
04:38:15
Wonderful presentation,
Faraj Tamimy
04:39:04
more centres need to be started for subspeciality training, eg cardio, gastro, pulmo etc
Henry Mwandumba
04:40:49
Fabulous talks, thank you Drs Saylor and Mateyo.
Raymond Madzivanyika
04:41:04
Thank you for the presentation Dr Mateyo. We have seen the GeneXpert machines being roped in to diagnose COVID. How has this impacted on TB diagnosis? Going forward are there prospects of maybe using the same sample to test for both TB and COVID at the same time on the GeneXpert machine?
Emmy Okello
04:41:31
Correct, there are already specialty trainings happening in individual institutions across different countries. We need to merge and have ECSACOP as the parent collegiate body awarding the fellowships.
Alick Nkhoma
04:41:54
RCP offers MTI subspecialty training as well. But local programs should be encouraged
Deanna Saylor
04:42:21
If there is anyone interested in joining our neurology learning activities or if you know anyone who may be interested, please feel free to email me directly or pass on my email to interested trainees/physicians: Deanna@jhmi.edu.
Lydia Nakiyingi
04:42:22
Thanks presenters and the audience. Wonderful discussions, keep them coming on the chat.
Mhoira Leng
05:38:49
In the interests of time perhaps any questions for this session can be posed and answered in chat?
Henry Mwandumba
05:39:51
Yes, that will be best. Will presenters look at the chat and respond to questions directed at them please?
Chiratidzo Ellen Ndhlovu
05:40:04
Lets us have your questions in the chat
Joseph Baruch Baluku
05:53:19
@sengooba, what lessons learnt from past viral hemorrhagic disease outbreaks were helpful in the covid 19 response in Uganda
Henry Mwandumba
05:54:48
Excellent talks, thank you to all presenters for the information.
Freddie Ssengooba
05:55:03
More epidemiological response and skilling of the workforce at the national and the sub-national level. There is also good diagnostic and surveillance capacity but COVID-19 was too wide and stretched all these capabilities.
Joseph Baruch Baluku
05:55:32
Thank you